This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Juno Therapeutics Inc.
Drug Names(s): T Cell Receptors (TCRs) Program, JTCR-016
T cells with high-affinity TCRs (T cell receptors) are modified with TCR sequences that bind more tightly to a target antigen/HLA complex. Thus, high-affinity TCR-based strategies can target tumor proteins inside the tumor cell. Further, given the association with an individual’s HLA proteins these cells are effective in only those patients who have the specific HLA molecule targeted by the high-affinity TCR.
This TCR T cell product targets WT-1 (Wilms' Tumor Protein-1), an intracellular protein overexpressed on a number of cancers.
Additional information available to subscribers only: